VIENNA — Ixekizumab (Taltz), an interleukin-17A inhibitor that's already approved for the treatment of psoriatic arthritis and axial spondyloarthritis in adults appears likely to be granted the same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback